Cronos Group (NASDAQ:CRON) Q4 results:
Revenue: $7.3M (+70.5%).
Net income: $61.6M (+735.1%) (due to $118.8M gain on revaluation of derivative liabilities); EPS: $0.16 (+420.0%).
$24.0M inventory write-down, principally due to downward pressure on cannabis prices.
Non-GAAP EBITDA: ($51.9M) (-794.8%).
Cash flow ops: ($53.2M) (-390.7%).
Group facilities remain open during COVID-19.
Interim financial statements for Q1, Q2 and Q3 2019 will be restated. Revenue reduced by C$2.5M and C$5.1M, respectively, in Q1 and Q3.